Cannabidiol (CBD) is increasingly recognized for its role as an antiseizure medication, especially for the management of Drug-Resistant Epilepsy (DRE). This ...

Synthetic cannabinoids, a class of new psychoactive substances, bind to cannabinoid receptors CB1 and CB2 much more strongly than tetrahydrocannabinol (THC) and cannabidiol (CBD), raising public ...

CBD-infused Products Market Expected to Grow at a CAGR of 30.6% from 2025 to 2032 REDDING, Calif., March 12, 2025 /PRNewswire/ -- According to a new market research report titled, 'CBD-infused ...

According to a new market research report titled, 'CBD-infused Products Market Size, Share, Forecast, & Trends Analysis by Source (Hemp), ...

Home Bargains fans have dubbed the oil a 'little bottle of heaven', which they swear helps them to 'sleep soundly.' ...

Kentucky legislative committee advances a ban on the sale of hemp-derived beverages in the state until summer of 2026.

A new group has been launched in the UK to champion the rights of medical cannabis patients facing discrimination.

Aldi has announced it will soon be offering a solution to people struggling with sleep as it launches a new product priced at ...

Avecho Biotechnology (ASX: AVE) has signed a ten-year development and licensing agreement with Sandoz (SWX: SDZ) for the ...

Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in AustraliaAvecho ...

Sandoz has agreed to an upfront licensing fee of US$3M (approx. A$4.8M [1]) for the exclusive commercial rights to the CBD product for insomnia in Australia. Avecho will continue to fund and oversee ...